AGP Executive Report
Last update: 5 minutes agoAbortion Law Update: Abortion activists are pushing another bid to modernise Liechtenstein’s strict abortion laws, but a hereditary prince has threatened to use his veto power again—echoing a past referendum defeat. Cancer Drug Deal: IMPACT Therapeutics and Pharmanovia signed an exclusive licensing agreement worth up to €423.5m, giving Pharmanovia rights to manufacture and commercialise senaparib across Europe (including Liechtenstein), plus parts of the Middle East and North Africa, Australia and New Zealand. COVID-19 Vaccines: The European Commission authorised Pfizer-BioNTech’s updated XFG-adapted COVID-19 vaccine for people 6 months and older, with validity across EU states plus Iceland, Liechtenstein and Norway. Hepatitis B Research: Researchers in Europe are working toward a “functional cure” for chronic hepatitis B, where today’s treatments can suppress the virus but can’t eliminate it; Liechtenstein is included in the EU-region infection estimates. Patient Safety & Counterfeits: Ivoclar is rolling out a verification approach for authorised dental product distributors to reduce risks from gray market and counterfeit items. Travel Insurance for Older People: Coverage options for older travellers are narrowing, with fewer insurers and stricter age limits shaping what people can buy.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
